For adults with moderate to severe hidradenitis suppurativa
COSENTYX® (secukinumab) IS THE FIRST MEDICINE OF ITS KIND† FOR HS
HS - Hidradenitis Suppurativa
Looking for an HS treatment with proven experience?
1st
COSENTYX is the first treatment of its kind† that targets IL-17A, a molecule thought to play a role in causing inflammation that contributes to HS symptoms. The way COSENTYX works in the body and how it affects HS symptoms is not fully known.
4.3+ MILLION
Before the FDA approved COSENTYX to treat adults with moderate to severe HS, over 4.3 million COSENTYX prescriptions had been filled‡ in the United States across all indications combined (not including HS).
16 YEARS
COSENTYX has been extensively studied for over 16 years across 8 conditions.
Get specific about HS.
Get the most out of your visits. Don’t be shy. Tell your doctor about all your symptoms and ask if COSENTYX® could be right for you.
†COSENTYX targets and blocks IL-17A, a molecule thought to play a role in the inflammation that may contribute to HS symptoms.
‡As of December 2023.
Individual results may vary. Frank was compensated for his time.
“It took 10 years for me to find out what the bumps under my chest were. When I was finally diagnosed with HS, I found out they were abscesses. I felt relieved and seen. My dermatologist told me about COSENTYX® and I was ready, honey!”
– Frank, actual patient
COSENTYX has had a well-studied safety profile since its launch in 2015 and has been approved to treat numerous conditions:
2015 — adults with moderate to severe plaque psoriasis
2016 — adults with active ankylosing spondylitis and active psoriatic arthritis
2020 — adults with active non-radiographic axial spondyloarthritis
2021 — children with plaque psoriasis (6 years and older), psoriatic arthritis (2 years and older), and enthesitis-related arthritis (4 years and older)
2023 — adults with moderate to severe hidradenitis suppurativa
